Lv31
362 积分 2023-12-20 加入
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
12天前
已完结
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
14天前
已关闭
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
14天前
已完结
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
16天前
已完结
Ethics of Backfilling in Early-Phase Oncology Trials
16天前
已完结
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
17天前
已完结
The next generation of immunotherapies for lung cancers
17天前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
18天前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
18天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells
22天前
已完结
皖公网安备34019202002308
